Boston: The 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics is underway (#Targets19). It’s long been one of our favorite meetings, particularly when held in Boston, and this year there’s a raft of early ideas on offer as to where the targeted therapy field may be going.

Alison Schram, MD. Credit: MSKCC

The success of Ignyta’s entrectinib (acquired by Roche) and Loxo Oncology’s larotrectinib (acquired by Lilly) in targeting NTRK gene fusions has raised interest in targeting other gene fusions, even if they are rare. A new target in a similar vein that has attracted interest recently are fusions involving the neuregulin 1 gene (NRG1).

At this year’s Molecular Targets meeting, Dr Alison Schram, a medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK) presented clinical proof of concept data for MCLA-128 (Merus), a bispecific HER2/3 antibody therapy in NRG1 fusion positive cancers.

What did we learn about MCLA-128 and NRG1 at Targets19?

To learn more from our Triple/Targets meeting oncology coverage and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers